Cambridge University Press & Assessment 978-1-009-01693-3 — Personalized Drug Screening for Functional Tumor Profiling Victoria El-Khoury , Tatiana Michel , Hichul Kim , Yong-Jun Kwon Frontmatter <u>More Information</u>

Cambridge Elements⁼</sup>

Elements in Molecular Oncology edited by Edward P. Gelmann University of Arizona

PERSONALIZED DRUG SCREENING FOR FUNCTIONAL TUMOR PROFILING

Victoria El-Khoury Luxembourg Institute of Health Tatiana Michel Luxembourg Institute of Health Hichul Kim Luxembourg Institute of Health Yong-Jun Kwon Luxembourg Institute of Health



Cambridge University Press & Assessment 978-1-009-01693-3 — Personalized Drug Screening for Functional Tumor Profiling Victoria El-Khoury, Tatiana Michel, Hichul Kim, Yong-Jun Kwon Frontmatter More Information

CAMBRIDGE UNIVERSITY PRESS

University Printing House, Cambridge CB2 8BS, United Kingdom

One Liberty Plaza, 20th Floor, New York, NY 10006, USA

477 Williamstown Road, Port Melbourne, VIC 3207, Australia

314–321, 3rd Floor, Plot 3, Splendor Forum, Jasola District Centre, New Delhi – 110025, India

103 Penang Road, #05–06/07, Visioncrest Commercial, Singapore 238467

Cambridge University Press is part of the University of Cambridge.

It furthers the University's mission by disseminating knowledge in the pursuit of education, learning, and research at the highest international levels of excellence.

www.cambridge.org Information on this title: www.cambridge.org/9781009016933 DOI: 10.1017/9781009037877

© Victoria El-Khoury, Tatiana Michel, Hichul Kim and Yong-Jun Kwon 2022

This publication is in copyright. Subject to statutory exception and to the provisions of relevant collective licensing agreements, no reproduction of any part may take place without the written permission of Cambridge University Press.

First published 2022

A catalogue record for this publication is available from the British Library.

ISBN 978-1-009-01693-3 Paperback ISSN 2634-7490 (online) ISSN 2634-7482 (print)

Cambridge University Press has no responsibility for the persistence or accuracy of URLs for external or third-party internet websites referred to in this publication and does not guarantee that any content on such websites is, or will remain, accurate or appropriate.

Every effort has been made in preparing this Element to provide accurate and up-to-date information which is in accord with accepted standards and practice at the time of publication. Although case histories are drawn from actual cases, every effort has been made to disguise the identities of the individuals involved. Nevertheless, the authors, editors and publishers can make no warranties that the information contained herein is totally free from error, not least because clinical standards are constantly changing through research and regulation. The authors, editors and publishers therefore disclaim all liability for direct or consequential damages resulting from the use of material contained in this book. Readers are strongly advised to pay careful attention to information provided by the manufacturer of any drugs or equipment that they plan to use. Cambridge University Press & Assessment 978-1-009-01693-3 — Personalized Drug Screening for Functional Tumor Profiling Victoria El-Khoury , Tatiana Michel , Hichul Kim , Yong-Jun Kwon Frontmatter <u>More Information</u>

Personalized Drug Screening for Functional Tumor Profiling

Elements in Molecular Oncology

DOI: 10.1017/9781009037877 First published online: June 2022

Victoria El-Khoury Luxembourg Institute of Health

Tatiana Michel Luxembourg Institute of Health

Hichul Kim Luxembourg Institute of Health

Yong-Jun Kwon Luxembourg Institute of Health

Author for correspondence: Victoria El-Khoury, Victoria.ElKhoury@lih.lu

Abstract: Despite considerable advances in our understanding of the biology that underlies tumor development and progression of cancer and the rapidly evolving field of personalized medicine, cancer is still one of the deadliest diseases. Many cancer patients have benefited from the survival improvements observed with targeted therapies but only a small subset of patients receiving targeted drugs experience an objective response. Because cancer is a complex and heterogeneous disease, the search for effective cancer treatments will need to address not only patient-specific molecular defects but also aspects of the tumor microenvironment. The functional tumor profiling directly measures the cellular phenotype, in particular tumor growth, in response to drugs using patient-derived tumor models and might be the next step toward precision oncology. In this Element, the authors discuss the personalized drug screening as a novel patient stratification strategy for the determination of individualized treatment choices in oncology.

Keywords: targeted therapy, personalized medicine, precision medicine, drug screening, personalized functional profiling

© Victoria El-Khoury, Tatiana Michel, Hichul Kim and Yong-Jun Kwon 2022

ISBNs: 9781009016933 (PB), 9781009037877 (OC) ISSNs: 2634-7490 (online), 2634-7482 (print) Cambridge University Press & Assessment 978-1-009-01693-3 — Personalized Drug Screening for Functional Tumor Profiling Victoria El-Khoury, Tatiana Michel, Hichul Kim, Yong-Jun Kwon Frontmatter <u>More Information</u>

Contents

| 1 | Rationale for Functional Profiling in Oncology | 1 |
|---|--|-----|
| 2 | Tumor Models in Drug Screening | 3 |
| 3 | Cell-Based Screening Platforms for Personalized Medicine | 8 |
| 4 | Drug Repurposing in Personalized Oncomedicine | 11 |
| 5 | Clinical Applications of Drug Screening in Oncology | 12 |
| 6 | Conclusions and Perspectives | 13 |
| | References | 15 |
| | Neierences | 1 J |